Brief: Sensei Biotherapeutics Provides Update On Strategic Priorities

Faeth Therapeutics,

08/12/2022 13:31

Dec 8 (Reuters) - Sensei Biotherapeutics Inc  SNSE.O :
    * SENSEI BIOTHERAPEUTICS PROVIDES UPDATE ON STRATEGIC
PRIORITIES
    * SENSEI BIOTHERAPEUTICS INC - CLOSES BOSTON RESEARCH SITE,
REDUCING WORKFORCE BY APPROXIMATELY 40 PERCENT TO DECREASE
OPERATING EXPENSES
    * SENSEI BIOTHERAPEUTICS - CONTINUED FOCUS ON DEVELOPMENT OF
TMAB
PROGRAMS; IND SUBMISSION FOR LEAD ANTIBODY SNS-101 ANTICIPATED
IN/PRIOR TO APRIL 2023
    * SENSEI BIOTHERAPEUTICS INC - CASH RUNWAY EXTENDED INTO
SECOND
HALF OF 2025
    * SENSEI - TO MAINTAIN ROCKVILLE, MARYLAND RESEARCH
FACILITY,
WHERE ANTIBODY DISCOVERY, PRODUCTION IN SUPPORT OF SNS-101,
OTHER TMAB PROGRAMS IS CONDUCTED
    * SENSEI BIOTHERAPEUTICS INC - MAINTAINING A SMALLER
BUSINESS
OFFICE IN BOSTON AREA
    * SENSEI BIOTHERAPEUTICS INC - PLANS TO RELOCATE ANY ONGOING
WORK
AT ITS BOSTON RESEARCH SITE TO ITS ROCKVILLE, MARYLAND SITE
    * SENSEI BIOTHERAPEUTICS INC - WILL CONTINUE DISCOVERY WORK
FOR
ITS DISCOVERY-STAGE PROGRAMS TARGETING VSIG-4 AND ENTPDASE1,
ALSO KNOWN AS CD39

Source text for Eikon:  ID:nGNX5SxJgY 
Further company coverage:  SNSE.O